Corcept Therapeutics Inc
CORT
Get informed when a big investor buys or sells
+ FollowMarket Cap$12.56B
Close$
$70.65
39.2% downside
Current Fair Value
39.2% downsideOvervalued by 39.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $12.56 Billion |
|---|---|
| Enterprise Value | $12.48 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.95 |
| Beta | 0.45 |
| Outstanding Shares | 105,377,000 |
Return
| Return on Equity | 7.73% |
|---|---|
| Return on Assets | 6.14% |
| Return on Invested Capital | 2.92% |
Valuation & Multiples
| P/E Ratio | 223.52 |
|---|---|
| PEG | 1027.39 |
| Price to Sales | 16.6 |
| Price to Book Ratio | 19.37 |
| Enterprise Value to Revenue | 15.02 |
| Enterprise Value to EBIT | 580.84 |
| Enterprise Value to Net Income | 228 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 30, 2026
EPS Estimate
$0.01
Average shareholder expectationRevenue Estimate
$219.13 M
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$0.81
Average shareholder expectationRevenue Estimate
$323.90 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.2663▼ 181.10% |
|---|---|
| Total Calls | 1,641,524▲ 59.79% |
| Total Puts | 437,100▼ 79.52% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 79.26%▲ 3.07% |
|---|---|
| Total Invested | $7.25B▲ 126.34% |
| Investors Holding | 451▲ 81.00% |
ESG Score
No data
About Corcept Therapeutics Inc
CEO: Joseph Belanoff Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym® was the first drug approved...